Breaking Down Xinjiang Zhongtai Chemical Co., Ltd. Financial Health: Key Insights for Investors

Investors dissecting Xinjiang Zhongtai Chemical Co., Ltd. will find a mixed financial portrait: 2024 revenue fell to CNY 30.12 billion (down 18.84% year‑on‑year) with TTM revenue as of 30‑Sep‑2025 at CNY 28.88 billion (‑1.53% YoY) while Q3‑2025 revenue ticked up to CNY 7.29 billion (+0.26% YoY); profitability shows a 2024 net loss narrowed to CNY 976.5 million (loss per share CNY 0.38) alongside a Q3‑2025 net income of CNY 14.90 million and quarterly EBITDA of CNY 1.19 billion, even as the effective tax rate hit 157.41%; the balance sheet at 30‑Sep‑2025 lists total assets of CNY 78.31 billion, liabilities of CNY 50.68 billion and equity of CNY 27.63 billion, producing a debt‑to‑equity ratio of about 1.83 and liabilities exceeding equity; liquidity shows CNY 6.83 billion in cash/short‑term investments but operating cash flow for Q3‑2025 plunged 89.52% to CNY 158.90 million with a net cash change of ‑CNY 519.33 million and free cash flow of CNY 2.44 billion (‑49.91% YoY); market signals include a 12‑Dec‑2025 share price of CNY 4.610, market cap ~CNY 11.94 billion, P/S 0.44 and P/B 0.56 with TTM EPS of ‑CNY 0.31 and beta 0.53; risk factors and growth initiatives-R&D spending ~CNY 350 million, planned CNY 1 billion for acquisitions, export targets and bio‑based collaborations-are documented alongside heavy reliance on imported methanol/ethylene, regulatory exposure, high leverage and competitive pressures-read on for a detailed, line‑by‑line financial breakdown and what each metric means for potential shareholders.

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) Revenue Analysis

• FY 2024 revenue: CNY 30.12 billion (down 18.84% vs FY 2023).
• TTM revenue as of 30‑Sep‑2025: CNY 28.88 billion (down 1.53% YoY).
• Quarter (Q3) ending 30‑Sep‑2025 revenue: CNY 7.29 billion (up 0.26% YoY).
• Total employees: 27,011; revenue per employee: ~CNY 1.07 million.

• Primary drivers of revenue decline: reduced demand in key domestic and international markets, intensified competitor pricing and capacity, and product mix shifts away from higher-margin specialty lines.
• Recent stabilization signs: modest sequential and quarterly improvement (Q3 2025 +0.26% YoY) but still below historical peaks.
• Operational implication: with revenue per employee at ~CNY 1.07 million, labor efficiency and asset utilization will be important levers to restore margins and absolute revenue.

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) - Profitability Metrics

Key recent profitability outcomes show a company moving from deep losses toward positive quarterly performance, while still carrying episodic tax and margin pressures.

• Fiscal year ending Dec 31, 2024: net loss CNY 976.5 million (improved 65.92% vs. 2023).
• Loss per share (2024): CNY 0.38, improved from CNY 1.11 in prior year.
• Quarter ending Sep 30, 2025: net income CNY 14.90 million, up 114.14% YoY.
• Net profit margin (Q3 2025): 0.20%, up 113.79% YoY.
• EBITDA (Q3 2025): CNY 1.19 billion, up 23.50% YoY.
• Effective tax rate (Q3 2025): 157.41%, indicating an unusually high tax burden in the quarter.

Implications for investors:

• Significant improvement in bottom-line dynamics from FY2024 loss to Q3 2025 profitability, suggesting operational recovery or favorable one-off items.
• Robust EBITDA (CNY 1.19B) signals underlying cash-generation capacity despite slim net margins (0.20% in Q3 2025).
• The extraordinarily high effective tax rate (157.41%) in Q3 2025 warrants scrutiny-possible deferred tax movements, non-deductible items, or one-time tax adjustments impacting net profit.
• EPS improvement (from loss of CNY 1.11 to loss of CNY 0.38 in FY2024) indicates shrinking per-share losses; continued positive quarterly results would be required to return to positive annual EPS.
• Volatility between annual loss and quarterly profit highlights the need to assess seasonality, commodity price exposure, and non-recurring items when forecasting future profitability.

For context on company direction and governance that may affect future profitability, see: Mission Statement, Vision, & Core Values (2026) of Xinjiang Zhongtai Chemical Co., Ltd.

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) - Debt vs. Equity Structure

• Total assets (30‑Sep‑2025): CNY 78.31 billion
• Total liabilities (30‑Sep‑2025): CNY 50.68 billion
• Total equity (30‑Sep‑2025): CNY 27.63 billion
• Debt-to-equity ratio (30‑Sep‑2025): ~1.83
• Liabilities exceed equity - debt load remains a principal concern
• Management is pursuing debt reduction, equity strengthening and debt restructuring options

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) - Liquidity and Solvency

Key balance sheet and cash flow snapshots as of September 30, 2025, highlight the company's short-term liquidity position and recent cash dynamics.

• Cash & short-term investments: CNY 6.83 billion (up 2.32% YoY)
• Cash flow from operations (Q3 2025): CNY 158.90 million (down 89.52% YoY)
• Net change in cash (Q3 2025): CNY -519.33 million (down 146.36% YoY)
• Free cash flow (Q3 2025): CNY 2.44 billion (down 49.91% YoY)
• Current ratio: not specified in available data
• Quick ratio: not specified in available data

For broader context on the company's history, ownership and business model, see: Xinjiang Zhongtai Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) - Valuation Analysis

Key valuation snapshots as of December 12, 2025 provide a concise view of how the market prices Xinjiang Zhongtai Chemical Co., Ltd. relative to its financials and risk profile.

• Low P/S of 0.44: investors are paying CNY 0.44 for every CNY 1 of sales, signaling a cheap revenue multiple relative to typical chemical peers.
• P/B of 0.56: the stock trades at roughly 56% of book value, implying the market values the company well below its net asset base.
• Negative EPS (-CNY 0.31 TTM): profitability weakness or one-off charges are forcing a valuation that discounts future earnings potential.
• Low beta (0.53): equity returns have shown lower volatility than the broader market - relevant for risk-adjusted allocation decisions.
• Market cap below annual revenue: a red flag for growth/profitability expectations; revenue scale exists but the market doubts sustainable margins or earnings conversion.

Implications for valuation frameworks:

• Relative valuation: P/S and P/B both favor the view that the stock is cheap versus peers; however, negative EPS complicates P/E-based comparisons.
• Asset-based approaches: with P/B at 0.56, a liquidation or break-up value lens would show substantial implied downside protection if asset valuations are sound.
• Discounted cash flow sensitivity: low beta reduces discount rates modestly, but persistent negative earnings require conservative cash-flow forecasts and higher distress premiums.

For investors seeking deeper ownership and transaction context, see: Exploring Xinjiang Zhongtai Chemical Co., Ltd. Investor Profile: Who's Buying and Why?

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) - Risk Factors

• Heavy reliance on imported feedstock: Xinjiang Zhongtai Chemical depends substantially on imported methanol, ethylene and other petrochemical inputs, leaving margins exposed to global commodity price swings and freight/logistics disruptions.
• Environmental compliance pressure: Chinese environmental policy tightening raises capex and operating costs (emissions control, wastewater treatment, monitoring), plus risk of fines or production curbs for non-compliance.
• Limited product diversification: Concentration in core chemical products increases vulnerability to sector-specific demand shocks and price cycles.
• Market-price volatility: Global chemical price fluctuations (methanol, PTA, ethylene derivatives) materially affect gross margins and EBITDA in the short-to-medium term.
• Leverage and interest coverage concerns: Elevated debt levels amplify refinancing and interest-rate risks, particularly in cyclical downturns.
• Intense competition: Domestic overcapacity and import competition pressure pricing, volumes and market share.

• Price input sensitivity: A 10% rise in methanol/ethylene costs can compress gross margin by several percentage points given the company's feedstock intensity; hedging practices and pass-through pricing are therefore critical.
• Regulatory shock scenarios: Temporary production suspensions or required retrofit investments (estimated in the hundreds of millions RMB for large plants) can cause capacity reductions and one-off costs.
• Refinancing risk: With notable short- and medium-term debt maturities, higher interest rates or tighter credit conditions could squeeze cash flow; maintaining liquidity buffers and access to bank lines matters.
• Operational concentration: Geographic or plant-level operational disruptions (logistics in Xinjiang, single-site outages) would disproportionately harm output and sales.
• Competitive pricing pressure: Lower-cost domestic peers or imports can force margin concessions; scale, integration and product mix improvements are key defensive levers.

• Key monitoring metrics for investors:
  • Feedstock price trends and hedging disclosures
  • Capex on environmental compliance and timelines
  • Debt maturity schedule and interest coverage ratio
  • Sales mix diversification and new product initiatives
  • Volume/realization trends vs. Chinese and global chemical indices

Xinjiang Zhongtai Chemical Co., Ltd. (002092.SZ) - Growth Opportunities

• R&D investment: ~CNY 350 million in the last fiscal year, resulting in multiple new product launches and expanded patent filings.
• Export expansion: target to increase exports by 25% in 2024, with priority markets in Southeast Asia and Europe.
• Capital deployment for M&A: ~CNY 1 billion earmarked for strategic acquisitions over the next two years to bolster production capacity and market share.
• Bio-based chemicals collaboration: partnerships with leading agricultural firms expected to add ~CNY 200 million in revenue by 2025.
• Automation & efficiency: technology partnerships aimed at automation are forecast to deliver ~CNY 50 million in annual cost savings.
• Analyst revenue outlook: revenue projected to grow from CNY 5.0 billion in 2023 to ~CNY 6.5 billion by 2025 (CAGR ≈ 14%).

• Strategic levers: new product commercialization from R&D spend, export scaling, targeted acquisitions, bio-based product rollouts, and automation-driven margin improvement.
• Execution risks: integration risk on M&A, export logistics and tariff exposure, timeline for automation ROI, and commercialization execution for bio-based lines.
• Key monitoring metrics for investors: quarterly revenue mix (domestic vs. export), R&D-to-revenue ratio, acquisition deployment schedule, incremental revenue from bio-based partnerships, and realized annualized cost savings from automation.